SELLING OFFER
Seek co-innovation with global enterprises and governmental institutions
Semi-universal Anti-viral Reagent
161 2022. 11. 3.
Summary
A science-based biotechnology company in South Korea is looking for a European R&D partner. The company makes efforts on sustainable development of a new form of anti-viral reagent which is less-dependent on the virus type. Because of the genetic diversity of novel and mutant viruses spreading recently, the company is in search of the efficiency and the safety of vaccine and anti-viral reagents. So they are making a progress toward development goals with an innovative approach to prepare the pandemic.
Advantages and Innovations
□ Their anti-viral reagent does not target at viral proteins but a common activation pathway in cells which are infected with many viruses, thereby being less-dependent on either virus type or mutation.
□ This anti-viral reagent has the upper hand in safety, cost, and handling.
□ This is a reliable technology which is already proved its safety by clinical trial.
Stage of Development
Description
In light of the strong evidence for the common correlation between virus infectivity and pathogenic substances in most virus-infected host, drugs that aim to block a major generation pathway of deteriorating substances facilitate the treatment of infection as well as improve host recovery, suggesting a therapeutic plan for the safe control of infection with novel or even mutant viruses. This anti-viral reagent is less-dependent on either virus type or mutation, thereby applying the therapeutic approach to antagonize virus replication and reduce host tissue damage as a general antiviral reagent.
Technology Keywords
Market Application Keywords
Sector Group
Type and Size of Client
Type and Role of Partner Sought
European R&D partner
Type of Partnership Considered
License agreement
Manufacturing agreement
Company
Internal Reference
Category
If interested, please press this button.
We will answer you soon.